2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|July 6, 2016
Teligent Breaks Ground on Manufacturing and R&D Expansion
Author(s)Pharmaceutical Technology Editors
Teligent is expanding its manufacturing and R&D complex in New Jersey.
Advertisement
Teligent, a New Jersey-based specialty generic-drug pharmaceutical company, held a formal groundbreaking ceremony for the ongoing expansion of its manufacturing and research and development complex in Buena, NJ, the company said in a July 6, 2016 press release. The $45â50 million project will increase the facility's footprint by more than 75,000 ft2, a 200% increase to current operations. Once completed, the expansion will include the installation of a new isolator-based sterile injectable manufacturing suite and will deliver a significant increase to the company's manufacturing capacity for topical pharmaceutical products.
''We are making very good progress on our expansion, and this ceremony was an opportunity to celebrate what we are building together,'' commented Teligent's president and CEO, Jason Grenfell-Gardner, in the press release. ''We continue to be on track for project completion by the end of 2017.''
Source:
Advertisement
Related to this article
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Advertisement
Advertisement